Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
Crossref DOI link: https://doi.org/10.1186/s12885-016-2568-7
Published Online: 2016-07-26
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nguyen, Linh
Fifis, Theodora
Christophi, Christopher
Funding for this research was provided by:
National Health and Medical Research Council (400190)
